Protocol Synopsis  
 
Title:  Multicenter Trial of the Sidus Stem -Free Shoulder Arthroplasty System  
Protocol No.:  CIU2012 -12E 
Sponsor:  Zimmer Inc.  
Objectives:  Primary Objectives  
The primary objectives of this study are to evaluate the safety and 
efficacy of the Sidus Stem -Free Shoulder System in unilateral primary 
total shoulder arthroplasty.  
 
Safety  will be evaluated by [CONTACT_380804] 
(UADEs) in investigational subjects as well as analyzing survivorship 
using revision or intended revision as an endpoint. 
 
Efficacy  will be determined by [CONTACT_380805] s. 
Indication/  
Target 
Population:  The Sidus Stem -Free Shoulder Syst em is indicated for uncemented use 
in total shoulder arthroplasty, replacing the shoulder joint of subjects 
suffering from severe pain or disability resulting from one or more of 
the following provided there is adequate bone stock to support the 
fixation o f the implants:  
• Osteoarthritis  
• Posttraumatic arthrosis  
• Rheumatoid arthritis without humeral metaphyseal defects  
• Previous shoulder surgeries that do not compromise fixation  
Study Design:  Multi- center, prospective, historical controlled.  
Clinical Phase:  Investigational Device Exemption Protocol / Pre -market  
Number of 
Subjects:  95 subjects will be enrolled in this study at up to 15 centers . 
 
 
Revised 20 May  2013  Confidential  Zimmer Inc.  
IRB Approved 30 July 2013 
 
Protocol Synopsis  
 
Title:  Multicenter Trial of the Sidus Stem -Free Shoulder Arthroplasty System  
Length of Study:  Initial follow -up will be [ADDRESS_477025] completes two years of follow -up.   
Investigational  
Device System:  • Zimmer Anatomical Shoulder  Glenoid 
• Sidus Humeral Head  
• Sidus  Stem -Free Anchor  
Scores:  • American Shoulder and Elbow Society Standardized Shoulder 
Assessment (ASES)  
• SF-12 
• Western Ontario Osteoarthritis Score (WOOS)   
Statistical  Analysis  Data collected will be summarized and reported to each participating 
Investigator. Statistical analysis is conducted by [CONTACT_380806].  
Primary data analysis will be completed after 2 years of follow -up. 
Documentation:  Electronic Data Capture . 
Anticipated 
Enrollment Date  Zimmer is currently  recruiting investigational sites.  
NOTE:  The investigation described by [CONTACT_380807] a significant risk device as defined by [CONTACT_380808] (IDE) regulation, Part  812, of the Code 
of Federal Regulations, Food and Drug Administration (FDA).  
 
Sidus Stem -Free 
Shoulder  
Revised 20 May  2013  Confidential  Zimmer Inc.  
IRB Approved 30 July 2013 
 